Case report demonstrates positive outcomes of dupilumab in treating atopic dermatitis in a patient with autosomal dominant polycystic kidney disease, indicating its safety.
This case report explores the management of a young female with both atopic dermatitis (AD) and autosomal dominant polycystic kidney disease (ADPKD), treated with dupilumab. Although these conditions are distinct, their coexistence poses clinical challenges. Dupilumab, a monoclonal antibody targeting interleukin (IL)-4 and IL-13, is effective for moderate-to-severe AD. This case highlights the safety and efficacy of dupilumab in ADPKD patients, with no adverse renal effects observed.
No takes yet. Share an insight, caveat, or question.
Kalaja et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: